Takeda Pharmaceutical (TAK) Change in Account Payables (2018 - 2026)

Takeda Pharmaceutical has reported Change in Account Payables for 9 years, with the latest figure at -$143.7 million in Q2 2026.

• On a quarterly basis, Change in Account Payables rose 25.13% year-over-year to -$143.7 million in Q2 2026; TTM through Jun 2026 was $20.5 million, a 178.28% increase from a year earlier, with the FY2026 full-year figure at -$20.1 million, up 57.02% from the prior year.
• Change in Account Payables was -$143.7 million for Q2 2026 at Takeda Pharmaceutical, down from $30.6 million in the prior quarter.
• The five-year high for Change in Account Payables was $1.1 billion in Q1 2022, with the low at -$751.0 million in Q2 2022.
• Average Change in Account Payables over 5 years is $8.4 million, with a median of -$26.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables slumped 302.34% in 2022, then surged 4352.61% in 2025.
• Over 5 years, Change in Account Payables stood at -$54.6 million in 2022, then surged by 970.94% to $475.4 million in 2023, then slumped by 72.84% to $129.1 million in 2024, then slumped by 83.43% to $21.4 million in 2025, then sank by 771.74% to -$143.7 million in 2026.
• The last three Change in Account Payables figures came in at -$143.7 million (Q2 2026), $30.6 million (Q1 2026), and $21.4 million (Q4 2025), per Business Quant data.